Search for: "Morris v. Merck "
Results 1 - 20
of 28
Sort by Relevance
|
Sort by Date
28 Apr 2024, 11:33 am
To give the reader some idea of the artificial flavor of Egilman’s pomposity, paragraph 8 of his remarkable declaration avers” “My views on the scientific standards for the determination of cause-effect relationships (medical epistemology) have been cited by the Massachusetts Supreme Court (Vassallo v. [read post]
23 Dec 2020, 5:31 am
In IPCom v HTC [2020] EWHC 2941 (Pat), IPCom sought to plead a similar point but Birss J took a harder line. [read post]
21 Feb 2019, 4:00 am
Court of Appeal’s ruling in R. v. [read post]
7 Nov 2014, 5:52 am
Ellis v. [read post]
20 Jun 2014, 8:25 am
Merck & Co., 195 N.J. 51, 948 A.2d 587 (2008). [read post]
21 Jun 2013, 6:43 pm
Philip Morris USA, Inc., 449 F. [read post]
15 Jun 2012, 2:08 pm
Merck & Co., 2006 U.S. [read post]
30 May 2012, 1:37 pm
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
15 Feb 2012, 7:42 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
14 Sep 2011, 12:08 pm
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
14 Sep 2011, 12:08 pm
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
14 Sep 2011, 12:07 pm
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
14 Sep 2011, 12:07 pm
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
9 Sep 2011, 8:40 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
2 Aug 2011, 9:25 am
KSR v. [read post]
22 Jun 2011, 7:09 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
15 Apr 2011, 6:02 am
Morris v. [read post]
11 Feb 2011, 7:51 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
4 Jan 2011, 2:45 pm
Papadopoulos v. [read post]
2 Oct 2010, 8:43 am
"These are legitimate concerns," concedes Lewis Morris, chief counsel for the Department of Health and Human Services’ unusually powerful Inspector General’s office, which is a key player in the search for ways to combat recidivism among pharmaceutical companies. [read post]
